aubagio
sanofi winthrop industrie - teriflunomide - multiple skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
pragiola 100 mg trde kapsule
krka, d.d., novo mesto - pregabalin - kapsula, trda - pregabalin 100 mg / 1 kapsula - pregabalin
pragiola 150 mg trde kapsule
krka, d.d., novo mesto - pregabalin - kapsula, trda - pregabalin 150 mg / 1 kapsula - pregabalin
pragiola 200 mg trde kapsule
krka, d.d., novo mesto - pregabalin - kapsula, trda - pregabalin 200 mg / 1 kapsula - pregabalin
pragiola 225 mg trde kapsule
krka, d.d., novo mesto - pregabalin - kapsula, trda - pregabalin 225 mg / 1 kapsula - pregabalin
pragiola 25 mg trde kapsule
krka, d.d., novo mesto - pregabalin - kapsula, trda - pregabalin 25 mg / 1 kapsula - pregabalin
pragiola 300 mg trde kapsule
krka, d.d., novo mesto - pregabalin - kapsula, trda - pregabalin 300 mg / 1 kapsula - pregabalin
pragiola 50 mg trde kapsule
krka, d.d., novo mesto - pregabalin - kapsula, trda - pregabalin 50 mg / 1 kapsula - pregabalin
pragiola 75 mg trde kapsule
krka, d.d., novo mesto - pregabalin - kapsula, trda - pregabalin 75 mg / 1 kapsula - pregabalin
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - multiplo sklerozo, recidivno-nakazila - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).